GORE EXCLUDER髂动脉分支支架真实世界注册研究五年结果
基于GREAT前瞻性多中心注册研究(NCT01658787)的回顾性分析,纳入94例常规临床实践中接受GORE EXCLUDER髂动脉分支支架(IBE)治疗的患者。5年全因死亡率为14.3%,主动脉相关死亡率为1.1%,累积再干预率为16.0%,内漏累积发生率为12.8%,器械完整性事件罕见。真实世界中IBE的中期结局与限制性IDE试验相当。
要点
- 5年主动脉相关死亡率仅1.1%,主动脉破裂率1.1%。
- 5年累积再干预率16.0%,器械相关再干预率15.0%。
- 内漏以II型(7.4%)和IB型(6.4%)为主,III型罕见(2.1%)。
核心结论
- 真实世界数据显示GORE EXCLUDER IBE的主动脉相关死亡、破裂、再干预、支架移位或断裂、动脉瘤增长及内漏发生率均较低。
- 其中期结局与限制性IDE试验报告的结果相当。
研究设计与样本
- 回顾性分析前瞻性多中心GREAT注册研究(NCT01658787)。
- 共纳入94例在常规临床实践中接受IBE治疗的患者。
主要发现
- 5年全因死亡率为14.3%,累积死亡率为23.4%,主动脉相关死亡率为1.1%。
- 5年累积再干预率为16.0%,其中器械相关再干预率为15.0%。
- 5年免于全因死亡为68.7%(57.4%-77.6%),免于主动脉相关死亡为98.8%(91.8%-99.8%)。
- 5年免于任何再干预为80.6%(69.7%-88.0%),免于器械或手术相关再干预为82.2%(71.5%-89.1%)。
- 5年内漏累积发生率为12.8%,其中II型7.4%、IB型6.4%、III型2.1%,无IV型内漏报告。
关键数值与推荐
- 5年器械完整性事件中仅报告1例支架移位。
- 主动脉破裂率为1.1%。
- 通畅性相关不良事件5年累积发生率为3.2%,多数事件发生在随访前2年。
临床怎么用
- 在真实世界临床实践中,IBE用于髂动脉分支治疗的中期结局良好,支持其常规应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study reports midterm outcomes for the GORE EXCLUDER Iliac Branch Endoprosthesis (IBE) for patients enrolled in the Global Registry for Endovascular Aortic Treatment (GREAT). METHODS: Retrospective analysis of the prospective, multicenter GREAT registry (NCT01658787) evaluated a total of 94 patients who received the IBE as part of routine clinical practice. RESULTS: The all-cause mortality rate among patients treated with IBE in the GREAT registry at 5 years was 14.3%, the cumulative mortality rate was 23.4%, and aortic-related mortality was 1.1%. The cumulative reintervention rate was 16.0% through 5 years including a device-related reintervention rate of 15.0%. Freedom from all-cause mortality and aortic-related mortality at 5 years was 68.7% (57.4%-77.6%) and 98.8% (91.8%-99.8%), respectively. Freedom from any reintervention and from device- or procedure-related reintervention through 5 years was 80.6% (69.7%-88.0%) and 82.2% (71.5%-89.1%), respectively. The cumulative rate of an endoleak through 5 years was 12.8%. Most endoleaks were type II (7.4%) and type IB (6.4%). Type III endoleaks were uncommon (2.1%), and no type IV endoleaks were reported. With regard to device integrity events, there was only a single instance of migration reported in 5 years. Aortic rupture was rare, with a rate of 1.1%. Patency-related adverse events were uncommon, with a cumulative incidence of 3.2% through 5 years with most events occurring during the first 2 years of follow-up. CONCLUSIONS: Our findings indicate that the GORE EXCLUDER IBE was associated with low rates of aortic-related mortality, aortic rupture, reintervention, endograft migration or fracture, aneurysm growth, and endoleak in a real-world setting. Midterm outcomes observed in this real-world registry were comparable to those reported in a more restrictive investigational device exemption trial.
引用
- Barber M, Schneider DB, Milner R, et al. Five-year outcomes of the GORE EXCLUDER Iliac Branch Endoprosthesis in real-world registry settings. J Vasc Surg. 2026. PMID: 42323113. doi:10.1016/j.jvs.2026.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。